Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615 · ACADIA Pharmaceuticals Inc. · PHASE2/PHASE3 · terminated · last registry update 2025-12-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated for business reasons and not due to safety concerns.” | – | Registry record, ACADIA Pharmaceuticals Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (terminated): Negovsky Reanimatology Research Institute, Sevoflurane + Propofol (NCT05259631)
- 2026-09-09Also stopped (terminated): Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2026-08-24Phase 3 first posted: Bukwang Pharmaceutical, Lurasidone + Placebo (NCT07781293)
- 2026-05-22Also stopped (terminated): OrthoCarolina Research Institute, Inc., a drug against HTR2A (NCT02202369)
- 2026-05-13Results posted on the registry: University Hospital, Clermont-Ferrand, Dexmedetomidine (NCT03317067)
- 2026-02-25Also stopped (terminated): Ohio State University, Clozapine + Antipsychotics,Other (non-Clozapine) (NCT05741502)
- 2026-02-11Phase 3 first posted: University of Michigan, Cyclobenzaprine (NCT07404397)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-11-24Phase 3 first posted: Mercy Bon Secours Saint Vincent Medical Center, Olanzapine 10 milligram + Haloperidol (NCT07246187)
- 2025-11-12Phase 3 first posted: NeuroRx, Inc., NRX-101 + Oral Placebo (NCT07227103)
- 2025-10-02Results posted on the registry: Northwestern University, aripiprazole (Abilify) + ziprasidone (Geodon) (NCT00288353)
- 2025-10-02Also stopped (terminated): Northwestern University, aripiprazole (Abilify) + ziprasidone (Geodon) (NCT00288353)
- 2025-09-16Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 + SPN-810 (NCT00626236)
- 2025-08-24Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin (NCT03121586)
- 2025-08-24Also stopped (terminated): ACADIA Pharmaceuticals Inc., Pimavanserin (NCT03121586)
- 2025-08-24Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin + Placebo (NCT05523895)
- 2025-07-29Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, Haloperidol + Metoclopramide 10mg (NCT02098499)
- 2025-06-06Phase 3 first posted: Md. Moktadirul Hoque Shuvo, Tablet Amitriptyline 10 milligrams + Tablet Trifluoperazine 1 milligrams twice daily (NCT07008235)
- 2025-05-21Results posted on the registry: Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-05-21Also stopped (terminated): Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-04-08Results posted on the registry: VA Palo Alto Health Care System, Ziprasidone + Placebo (NCT01172652)
- 2025-04-01Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin + Placebo (NCT04531982)
- 2025-02-28Results posted on the registry: Northwestern University, Lurasidone + Lurasidone (NCT01569659)
- 2025-02-25Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL Tablet, 2.8 mg + Placebo SL Tablet (NCT02829814)
- 2025-02-25Also stopped (terminated): Tonix Pharmaceuticals, Inc., TNX-102 SL Tablet, 2.8 mg + Placebo SL Tablet (NCT02829814)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision